A 61-year-old woman with rheumatoid arthritis who was undergoing hemodialysis for end-stage renal failure was transferred to our hospital due to severe thrombocytopenia and anemia. A bone marrow biopsy showed the complete absence of megakaryocytes and erythroblasts. Cyclosporine treatment resulted in the improvement of her megakaryocyte and erythroblast levels, and a decrease in her serum level of anti-c-Mpl (thrombopoietin receptor) antibodies. After this initial improvement, her anemia progressively worsened, despite the continuous administration of immunosuppressive therapy with cyclosporine. Her platelet and leukocyte counts remained stable. This is the first report of a probable case of anti-c-Mpl antibody-associated pure red cell aplasia and acquired amegakaryocytic thrombocytopenic purpura.
Introduction
Thrombopoietin (TPO) is the principal hematopoietic growth factor for stimulating the proliferation and maturation of megakaryocyte progenitor cells (1, 2) . TPO receptor c-Mpl is expressed on hematopoietic stem cells (HSCs) and progenitor cells (HPCs) (3) . TPO/MPL signaling plays an important role in the maintenance and regulation of HSCs and is indispensable for the maintenance of multipotent progenitors (MPPs) and their transition to common megakaryocyte-erythrocyte progenitors (MEPs) (4) . To the best of our knowledge, this is the first report of a patient with (probable) pure red cell aplasia (PRCA) with acquired amegakaryocytic thrombocytopenic purpura (AATP), a rare disorder that is characterized by thrombocytopenia causing the total absence or a marked reduction of megakaryocytes in the bone marrow (5) , and which is associated with anti-cMpl antibodies.
Case Report
A 61-year-old Japanese woman with a 25-year history of rheumatoid arthritis (RA) received care at the rheumatology department of another hospital. The patient had end-stage renal failure due to type 2 diabetes mellitus and started hemodialysis treatment three times per week in June 2007. Recombinant human erythropoietin (rHuEPO; epoetin and darbepoetin) was administered for the treatment of her renal anemia. Her laboratory test results were as follows: hemoglobin, 5.6 g/dL; white blood cell count, 4,400/μL; platelet count, 41.9×10 4 /μL; and reticulocyte count, 4.9×10 4 /μL. She began receiving red blood cell transfusions regularly in December 2009. The frequency of transfusions gradually increased, despite an increase in rHuEPO dosage. In May 2010, a marked decrease in her peripheral platelet counts was observed. This was followed by severe recurrent bleeding. During this period, the patient did not undergo bone marrow aspiration or biopsy. She was referred to our hospital in June 2011 to receive treatment for severe anemia and thrombocytopenia. There was nothing in her medical history that was suggestive of a viral infection, drug or alcohol abuse, or any other relevant causative agent or form of exposure. A physical examination revealed pale palpebral conjunctiva, intraoral hematomas, and multiple petechiae and ecchymoses on her trunk and extremities. There was no lymphadenopathy or organomegaly. She also had diabetic peripheral neuropathy and symmetrical polyarthritis with swelling and tenderness. Her RA Disease Activity Score (DAS28-CRP) was 3.2.
The laboratory test results on admission were as follows: hemoglobin, 5.3 g/dL; white blood cell count, 4,500/μL; and platelet count, 0.4×10 4 /μL (Table) . A peripheral blood smear analysis demonstrated no abnormalities, and there was no noticeable dysplasia. Large granular lymphocytes were not detected, and coagulation assays revealed no evidence of disseminated intravascular coagulation. Paroxysmal nocturnal hemoglobinuria clones were undetectable. Tests for an antiplatelet antibodies, antierythropoietin (EPO) antibodies, and anti-EPO receptor antibodies were negative. Although we did not perform assays for anti-TPO antibodies, the serum TPO level was elevated (6.12 Fmol/mL; reference range: 0.44-1.14 Fmol/mL). The serum level of anti-c-Mpl antibodies was 45.9 U (reference range: <18.0 U). There was no active viral infection. A bone marrow biopsy showed hypocellular marrow with the complete absence of megakaryocytes and erythroblasts without any dysplasia of a myeloid lineage (Fig. 1) . There was no proliferation of blasts. Flow cytometry did not reveal any evidence of monoclonality or malignancy, and the bone marrow cytogenetic findings were normal. The results of a T-cell receptor gene rearrangement test were negative. There was no evidence of thymoma. She rejected a magnetic resonance imaging examination due to claustrophobia. Anti-c-Mpl antibodymediated thrombocytopenia was recently demonstrated in patients with systemic lupus erythematosus (SLE). The pathogenesis of thrombocytopenia and anemia in the present case suggested that immunological mechanisms played important roles in its development. We also took the diagnoses of AATP and PRCA into account, which were made according to the clinical and laboratory results.
Antithymocyte globulin (ATG) plus cyclosporine, and cyclosporine (as a monotherapy) have been demonstrated to be effective for the treatment of AATP and/or PRCA in several case reports (6) . However, because our patient had poorly controlled type 2 diabetes we decided to use the cyclosporine monotherapy and not ATG, so as to avoid the use of corticosteroids. The patient started treatment with cyclosporine (150 mg, orally twice daily), with a target serum level. After 45 days, a gradual improvement was observed in her reticulocyte and platelet counts. Transfusions of platelets and red blood cells were no longer required. Bone marrow aspiration and a biopsy, which were performed at this time, revealed the appearance of megakaryocytes and an erythro- However, in June 2012 she presented with increasing joint pain, fever, paresthesia, and numbness, despite receiving ongoing treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (5 mg/day), etanercept (25 mg, subcutaneously every 7 days), and tocilizumab (8 mg/kg, intravenously every 4 weeks). She had a high level of RA disease activity (DAS-28=6.7). In addition, her hemoglobin level decreased to 5.7 g/dL, with a reticulocyte count of 0.2×10 4 /μL, which necessitated regular blood transfusions in September 2012. Her platelet count remained stable, averaging 10.0×10 4 /μL. She died of a traumatic intracerebral hemorrhage (Fig. 2) .
Discussion
The clinical course of our case is informative in the following aspects. First, thrombocytopenia and anemia were alleviated by the administration of cyclosporine. This also achieved a decrease in the patient's anti-c-Mpl antibody level. Second, our patient simultaneously developed two different lineage-restricted bone marrow failures: thrombocytopenia and anemia.
The c-Mpl protein is expressed on the surface of megakaryocytes, HSCs, and their progenitors (3). In addition to its role in megakaryopoiesis (7), the TPO/c-Mpl system performs an essential function in the self-renewal and expansion of HSCs (8, 9) . TPO and c-Mpl knockout mice show reduced HSC function and numbers (10), multilineage marrow failure develops in patients with congenital amegakaryocytic thrombocytopenia (CAMT) who have a cMpl mutation (11) . The administration of eltrombopag alleviates pancytopenia in some patients with aplastic anemia and severe persistent thrombocytopenia (12) . These findings prove that TPO/MPL signaling is one of the key pathways among the regulatory mechanisms underlying HSC maintenance. Anti-c-Mpl antibodies were detected in a subset of SLE patients who had thrombocytopenia and in those with idiopathic thrombocytopenia (13) . Anti-c-Mpl antibodies interfere with the TPO function by blocking its binding to c-Mpl (when expressed), resulting in thrombocytopenia with megakaryocytic hypoplasia (14) . In our patient, who had RA, the serum level of anti-c-Mpl antibodies decreased significantly after 45 days of cyclosporine treatment. Subsequently, there were gradual increases in her reticulocyte and platelet counts. It is likely that the thrombocytopenia and anemia can be mediated by anti-c-Mpl antibodies. In addition, we considered the diagnosis of AATP and PRCA based on the results of a bone marrow examination, which revealed the complete absence of megakaryocytes and erythro- Recently, Hirata et al. analyzed induced pluripotent stem cells derived from a patient with CAMT and demonstrated that MPL signaling is indispensable for the maintenance of MPPs and for the transition from MPPs to MEPs during early hematopoiesis. The absence of functional MPL leads to deficiencies in both erythropoiesis and megakaryopoiesis, although some development of myeloid cells is retained (4) . These reports suggested the possibility that, in our case, the inhibitory effect of anti-c-Mpl antibodies on MEP proliferation occurred due to the total absence of both megakaryocytes and erythroblasts. Moreover, the use of TPO receptor mimetic agents in AATP appears to be a logical choice because it may be able to bypass the blockade by autoantibodies to c-Mpl.
It should be mentioned that the hemoglobin level and reticulocyte counts decreased, despite the continuous administration of cyclosporine, while the platelet and leukocyte counts were maintained after the autumn of 2012. The anti-c-Mpl antibody titer normalized in May of the same year, but the subsequent measurement did not reach. Our patient was treated with various types of medicine, including erythropoietin, NSAIDs, and biological agents, due to the high activity of her RA. It is presumed that the mechanism underlying the recurrence of her anemia was different from the repressive effect of the anti-c-Mpl antibodies on erythropoiesis, and that it was associated with other causes, including multiple drug use, and the presence of comorbidities.
In conclusion, our case highlighted the pivotal role of anti-c-Mpl antibodies in the pathogenesis of thrombocytopenia and anemia, and also raised the possibility of a new therapeutic strategy for AATP using TPO receptor agonists. Further investigation is necessary to clarify the biological mechanisms that underlie these unusual diseases.
The authors state that they have no Conflict of Interest (COI).
